168 related articles for article (PubMed ID: 35493455)
1. Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.
Reiter A; Lefevre G; Cid MC; Kwon N; Mavropolou E; Yancey SW; Steinfeld J
Front Immunol; 2022; 13():840974. PubMed ID: 35493455
[TBL] [Abstract][Full Text] [Related]
2. Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome.
Pane F; Lefevre G; Kwon N; Bentley JH; Yancey SW; Steinfeld J
Front Immunol; 2022; 13():935996. PubMed ID: 36091012
[TBL] [Abstract][Full Text] [Related]
3. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
Rothenberg ME; Roufosse F; Faguer S; Gleich GJ; Steinfeld J; Yancey SW; Mavropoulou E; Kwon N;
J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2367-2374.e3. PubMed ID: 35568330
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
Roufosse F; Kahn JE; Rothenberg ME; Wardlaw AJ; Klion AD; Kirby SY; Gilson MJ; Bentley JH; Bradford ES; Yancey SW; Steinfeld J; Gleich GJ;
J Allergy Clin Immunol; 2020 Dec; 146(6):1397-1405. PubMed ID: 32956756
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study.
Gleich GJ; Roufosse F; Chupp G; Faguer S; Walz B; Reiter A; Yancey SW; Bentley JH; Steinfeld J;
J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4431-4440.e1. PubMed ID: 34389506
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
Kuang FL; Fay MP; Ware J; Wetzler L; Holland-Thomas N; Brown T; Ortega H; Steinfeld J; Khoury P; Klion AD
J Allergy Clin Immunol Pract; 2018; 6(5):1518-1527.e5. PubMed ID: 29751154
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
8. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
9. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
Roufosse FE; Kahn JE; Gleich GJ; Schwartz LB; Singh AD; Rosenwasser LJ; Denburg JA; Ring J; Rothenberg ME; Sheikh J; Haig AE; Mallett SA; Templeton DN; Ortega HG; Klion AD
J Allergy Clin Immunol; 2013 Feb; 131(2):461-7.e1-5. PubMed ID: 23040887
[TBL] [Abstract][Full Text] [Related]
11. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
12. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
13. Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome.
Roufosse F; Butterfield J; Steinfeld J; Bentley JH; von Maltzahn R; Kwon N; Nelsen L
Front Med (Lausanne); 2023; 10():1035250. PubMed ID: 37064032
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
15. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
[TBL] [Abstract][Full Text] [Related]
16. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
Williams AK; Dou C; Chen LYC
Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
[TBL] [Abstract][Full Text] [Related]
18. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Akuthota P; Jayne D; Khoury P; Klion A; Langford CA; Merkel PA; Moosig F; Specks U; Cid MC; Luqmani R; Brown J; Mallett S; Philipson R; Yancey SW; Steinfeld J; Weller PF; Gleich GJ;
N Engl J Med; 2017 May; 376(20):1921-1932. PubMed ID: 28514601
[TBL] [Abstract][Full Text] [Related]
19. Hypereosinophilic syndrome: an update.
Wilkins HJ; Crane MM; Copeland K; Williams WV
Am J Hematol; 2005 Oct; 80(2):148-57. PubMed ID: 16184589
[TBL] [Abstract][Full Text] [Related]
20. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
